The prognostic value of ¹⁸F-PSMA-1007 PET/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy.

ABSTRACT:

Objective

This study aimed to evaluate predictors for upgrading of newly diagnosed prostate cancer from systematic biopsy (SB) to radical prostatectomy (RP) using fluorine-18 prostate-specific membrane antigen 1007 (¹⁸F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) and association with clinical parameters.

Materials and methods

We retrospectively collected data from biopsy-confirmed prostate cancer (PCa) patients who underwent ¹⁸F-PSMA-1007 PET/CT prior to RP from July 2019 and October 2022. Imaging characteristics derived from ¹⁸F-PSMA-1007 PET/CT and clinical parameters were compared in patients of pathological upgrading and concordance subgroups. Univariable and multivariable logistic regressions were performed to an

SUBMITTER: Zheng A 

PROVIDER: S-EPMC10206242 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature